Cholesterol, lipoproteins, high-sensitivity c-reactive protein, and other risk factors for atherosclerosis

Clinics in Laboratory Medicine

Volumn 34, Issue 1, 2014, Pages 113-127

  Rudolf, Joseph ^a   Lewandrowski, Kent B ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Apolipoprotein E; Atherosclerosis; Biomarkers; Cardiac markers; Cholesterol biomarker; High sensitivity CRP; Laboratory medicine; Lipoprotein

Indexed keywords

APOLIPOPROTEIN E; ATHEROSCLEROSIS; BIOMARKERS; CARDIAC MARKERS; CHOLESTEROL BIOMARKER; HIGH-SENSITIVITY CRP; LABORATORY MEDICINE; LIPOPROTEIN;

APOLIPOPROTEINS E; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CHOLESTEROL; CORONARY ARTERY DISEASE; HUMANS; LIPOPROTEINS; POLYMORPHISM, GENETIC; PROPROTEIN CONVERTASES; RISK FACTORS; SERINE ENDOPEPTIDASES;

EID: 84895100162     PISSN: 02722712     EISSN: 15579832     Source Type: Journal    
DOI: 10.1016/j.cll.2013.11.003     Document Type: Review

References (50)

1. Roger V.L., Go A.S., Lloyd-Jones D.M., et al. Heart disease and stroke statistics-2012 update: a report from the American Heart Association. Circulation 2012, 125(1):e2-e220.
2. Lloyd-Jones D.M., Hong Y., Labarthe D., et al. Defining and setting national goals for cardiovascular health promotion and disease reduction: the American Heart Association's strategic impact goal through 2020 and beyond. Circulation 2010, 121(4):586-613.
3. Kumar V., Abbas A., Fausto N., et al. Robbins and Cotran pathologic basis of disease 2010, Saunders Elsevier, Philadelphia. 8th edition.
4. Ross R. Atherosclerosis-an inflammatory disease. NEngl J Med 1999, 340(2):115-126.
5. Ábel G., Laposata M. Lipids, lipoproteins, and cardiovascular risk. Clinical chemistry: laboratory management and clinical correlations 2002, 575-591. Lippincott Williams & Wilkins, Philadelphia. K. Lewandrowski (Ed.).
6. Langlois M.R. Laboratory approaches for predicting and managing the risk of cardiovascular disease: postanalytical opportunities of lipid and lipoprotein testing. Clin Chem Lab Med 2012, 50(7):1169-1181.
7. Ashen M.D., Blumenthal R.S. Clinical practice. Low HDL cholesterol levels. NEngl J Med 2005, 353(12):1252-1260.
8. Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002, 106(25):3143-3421.
9. Brewer H.B. Increasing HDL cholesterol levels. NEngl J Med 2004, 350(15):1491-1494.
10. Barter P., Gotto A.M., LaRosa J.C., et al. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. NEngl J Med 2007, 357(13):1301-1310.
11. Abudu N., Levinson S.S. Calculated low-density lipoprotein cholesterol remains a viable and important test for screening and targeting therapy. Clin Chem Lab Med 2007, 45(10):1319-1325.
12. Mueller O., Chang E., Deng D., et al. PROCAM Study: risk prediction for myocardial infarction using microfluidic high-density lipoprotein (HDL) subfractionation is independent of HDL cholesterol. Clin Chem Lab Med 2008, 46(4):490-498.
13. Rasouli M., Kiasari A.M., Mokhberi V. The ratio of apoB/apoAI, apoB and lipoprotein(a) are the best predictors of stable coronary artery disease. Clin Chem Lab Med 2006, 44(8):1015-1021.
14. Genest J., Frohlich J., Fodor G., et al. Recommendations for the management of dyslipidemia and the prevention of cardiovascular disease: summary of the 2003 update. CMAJ 2003, 169(9):921-924.
15. Anderson T.J., Gregoire J., Hegele R.A., et al. 2012 update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult. Can J Cardiol 2013, 29(2):151-167.
16. Master S.R., Rader D.J. Beyond LDL cholesterol in assessing cardiovascular risk: apo B or LDL-P?. Clin Chem 2013, 59(5):723-725.
17. Cole T.G., Contois J.H., Csako G., et al. Association of apolipoprotein B and nuclear magnetic resonance spectroscopy-derived LDL particle number with outcomes in 25 clinical studies: assessment by the AACC Lipoprotein and Vascular Diseases Division Working Group on Best Practices. Clin Chem 2013, 59(5):752-770.
18. Gilstrap L.G., Wang T.J. Biomarkers and cardiovascular risk assessment for primary prevention: an update. Clin Chem 2012, 58(1):72-82.
19. Verhoye E., Langlois M.R., Asklepios I. Circulating oxidized low-density lipoprotein: a biomarker of atherosclerosis and cardiovascular risk?. Clin Chem Lab Med 2009, 47(2):128-137.
20. Morrow D.A., de Lemos J.A. Benchmarks for the assessment of novel cardiovascular biomarkers. Circulation 2007, 115(8):949-952.
21. Devaraj S., Kumaresan P.R., Jialal I. C-reactive protein induces release of both endothelial microparticles and circulating endothelial cells invitro and invivo: further evidence of endothelial dysfunction. Clin Chem 2011, 57(12):1757-1761.
22. Mora S., Musunuru K., Blumenthal R.S. The clinical utility of high-sensitivity C-reactive protein in cardiovascular disease and the potential implication of JUPITER on current practice guidelines. Clin Chem 2009, 55(2):219-228.
23. Cook N.R., Paynter N.P., Manson J.E., et al. Clinical utility of lipoprotein-associated phospholipase A(2) for cardiovascular disease prediction in a multiethnic cohort of women. Clin Chem 2012, 58(9):1352-1363.
24. Ledue T.B., Rifai N. Preanalytic and analytic sources of variations in C-reactive protein measurement: implications for cardiovascular disease risk assessment. Clin Chem 2003, 49(8):1258-1271.
25. Ridker P.M., Cannon C.P., Morrow D., et al. C-reactive protein levels and outcomes after statin therapy. NEngl J Med 2005, 352(1):20-28.
26. Mora S., Ridker P.M. Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER)-can C-reactive protein be used to target statin therapy in primary prevention?. Am J Cardiol 2006, 97(2A):33A-41A.
27. Ridker P.M., Danielson E., Fonseca F.A., et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. NEngl J Med 2008, 359(21):2195-2207.
28. Biasucci L.M., Biasillo G., Stefanelli A. Inflammatory markers, cholesterol and statins: pathophysiological role and clinical importance. Clin Chem Lab Med 2010, 48(12):1685-1691.
29. Ridker P.M., Rifai N., Rose L., et al. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. NEngl J Med 2002, 347(20):1557-1565.
30. Yousuf O., Mohanty B.D., Martin S.S., et al. High-sensitivity C-reactive protein and cardiovascular disease: a resolute belief or an elusive link?. JAm Coll Cardiol 2013, 62(5):397-408.
31. Ruckerl R., Peters A., Khuseyinova N., et al. Determinants of the acute-phase protein C-reactive protein in myocardial infarction survivors: the role of comorbidities and environmental factors. Clin Chem 2009, 55(2):322-335.
32. Garza C.A., Montori V.M., McConnell J.P., et al. Association between lipoprotein-associated phospholipase A2 and cardiovascular disease: a systematic review. Mayo Clin Proc 2007, 82(2):159-165.
33. Kolasa-Trela R., Fil K., Bazanek M., et al. Lipoprotein-associated phospholipase A2 is elevated in patients with severe aortic valve stenosis without clinically overt atherosclerosis. Clin Chem Lab Med 2012, 50(10):1825-1831.
34. Stein E.A. Lipoprotein-associated phospholipase A(2) measurements: mass, activity, but little productivity. Clin Chem 2012, 58(5):814-817.
35. Thompson A., Gao P., Orfei L., et al. Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies. Lancet 2010, 375(9725):1536-1544.
36. Shao B., Oda M.N., Oram J.F., et al. Myeloperoxidase: an oxidative pathway for generating dysfunctional high-density lipoprotein. Chem Res Toxicol 2010, 23(3):447-454.
37. Kameda T., Usami Y., Shimada S., et al. Determination of myeloperoxidase-induced apoAI-apoAII heterodimers in high-density lipoprotein. Ann Clin Lab Sci 2012, 42(4):384-391.
38. Nordestgaard B.G., Chapman M.J., Ray K., et al. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J 2010, 31(23):2844-2853.
39. Kronenberg F., Utermann G. Lipoprotein(a): resurrected by genetics. JIntern Med 2013, 273(1):6-30.
40. Erqou S., Kaptoge S., Perry P.L., et al. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA 2009, 302(4):412-423.
41. Boden W.E., Probstfield J.L., Anderson T., et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. NEngl J Med 2011, 365(24):2255-2267.
42. Zeller T., Blankenberg S., Diemert P. Genomewide association studies in cardiovascular disease-an update 2011. Clin Chem 2012, 58(1):92-103.
43. Samani N.J., Erdmann J., Hall A.S., et al. Genomewide association analysis of coronary artery disease. NEngl J Med 2007, 357(5):443-453.
44. Linsel-Nitschke P., Heeren J., Aherrahrou Z., et al. Genetic variation at chromosome 1p13.3 affects sortilin mRNA expression, cellular LDL-uptake and serum LDL levels which translates to the risk of coronary artery disease. Atherosclerosis 2010, 208(1):183-189.
45. Burman D., Mente A., Hegele R.A., et al. Relationship of the ApoE polymorphism to plasma lipid traits among South Asians, Chinese, and Europeans living in Canada. Atherosclerosis 2009, 203(1):192-200.
46. Gronroos P., Raitakari O.T., Kahonen M., et al. Association of high sensitive C-reactive protein with apolipoprotein E polymorphism in children and young adults: the Cardiovascular Risk in Young Finns Study. Clin Chem Lab Med 2008, 46(2):179-186.
47. Chmielewski M., Verduijn M., Dekker F.W. ApoE genotype as risk factor in dialysis patients. Atherosclerosis 2010, 212(2):695-696. [author reply: 697].
48. Clarke R., Peden J.F., Hopewell J.C., et al. Genetic variants associated with Lp(a) lipoprotein level and coronary disease. NEngl J Med 2009, 361(26):2518-2528.
49. Stein E.A., Swergold G.D. Potential of proprotein convertase subtilisin/kexin type 9 based therapeutics. Curr Atheroscler Rep 2013, 15(3):310.
50. Stein E.A., Mellis S., Yancopoulos G.D., et al. Effect of a monoclonal antibody to PCSK9 on LDL cholesterol. NEngl J Med 2012, 366(12):1108-1118.